Amylyx Pharmaceuticals, Inc. Logo

Amylyx Pharmaceuticals, Inc.

Developing novel therapies for neurodegenerative diseases like ALS and Wolfram syndrome.

AMLX | US

Overview

Corporate Details

ISIN(s):
US0321085088
LEI:
Country:
United States of America
Address:
43 THORNDIKE STREET, 2141 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing novel treatments for neurodegenerative diseases and other conditions with high unmet medical needs. The company advances a pipeline of investigational therapies based on rigorous science and well-defined mechanistic rationale. Key areas of focus in its pipeline include Amyotrophic Lateral Sclerosis (ALS), Wolfram syndrome, and Post-Bariatric Hypoglycemia. Amylyx is committed to a patient-centric approach, aiming to provide solutions for some of medicine's most complex challenges.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Amylyx Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Amylyx Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Amylyx Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel LCTX
Lineage Cell Therapeutics, Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
United States of America LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN

Talk to a Data Expert

Have a question? We'll get back to you promptly.